Total Payments
$33,817
2024 Payments
$32.27
Companies
3
Transactions
21
Medicare Patients
62
Medicare Billing
$10,768
Payment Breakdown by Category
Research$20,221 (59.8%)
Consulting$11,900 (35.2%)
Other$1,567 (4.6%)
Education$129.08 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,221 | 7 | 59.8% |
| Consulting Fee | $11,900 | 7 | 35.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,524 | 2 | 4.5% |
| Education | $129.08 | 4 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $43.36 | 1 | 0.1% |
Payments by Type
Research
$20,221
7 transactions
General
$13,596
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $33,645 | 16 | $0 (2021) |
| Novo Nordisk Inc | $129.08 | 4 | $0 (2024) |
| Servier Pharmaceuticals LLC | $43.36 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.27 | 1 | Novo Nordisk Inc ($32.27) |
| 2023 | $96.81 | 3 | Novo Nordisk Inc ($96.81) |
| 2021 | $1,843 | 2 | Celgene Corporation ($1,800) |
| 2020 | $2,100 | 2 | Celgene Corporation ($2,100) |
| 2019 | $7,212 | 3 | Celgene Corporation ($7,212) |
| 2018 | $15,868 | 6 | Celgene Corporation ($15,868) |
| 2017 | $6,665 | 4 | Celgene Corporation ($6,665) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 12/15/2023 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 12/15/2023 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 12/15/2023 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $43.36 | General |
| Category: ONCOLOGY | ||||||
| 01/22/2021 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Hematology | ||||||
| 08/20/2020 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Hematology | ||||||
| 01/30/2020 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Hematology | ||||||
| 09/26/2019 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Hematology / Oncology | ||||||
| 05/31/2019 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $4,962.00 | Research |
| Study: Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | ||||||
| 01/10/2019 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Hematology / Oncology | ||||||
| 10/24/2018 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Hematology / Oncology | ||||||
| 09/12/2018 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,082.00 | General |
| Category: Hematology / Oncology | ||||||
| 05/31/2018 | Celgene Corporation | Revlimid (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $442.00 | General |
| Category: Hematology / Oncology | ||||||
| 03/14/2018 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $4,022.00 | Research |
| Study: AZA-MDS-004 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDIN | ||||||
| 02/13/2018 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $4,572.00 | Research |
| Study: AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | ||||||
| 01/25/2018 | Celgene Corporation | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $3,350.00 | General |
| Category: Hematology / Oncology | ||||||
| 10/07/2017 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $3,111.00 | Research |
| Study: AZA-MDS-004 | ||||||
| 07/10/2017 | Celgene Corporation | Revlimid (Drug) | — | In-kind items and services | $578.00 | Research |
| Study: Retrospective Cohort Study SEER-Medicare Population • Category: Hematology / Oncology | ||||||
| 02/07/2017 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $834.00 | Research |
| Study: AZA-MDS-006 | ||||||
| 02/06/2017 | Celgene Corporation | Vidaza (Drug) | — | In-kind items and services | $2,142.00 | Research |
| Study: AZA-MDS-006 • Category: Hematology / Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | Celgene Corporation | $4,962 | 1 |
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $4,572 | 1 |
| AZA-MDS-004 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDIN | Celgene Corporation | $4,022 | 1 |
| AZA-MDS-004 | Celgene Corporation | $3,111 | 1 |
| AZA-MDS-006 | Celgene Corporation | $2,976 | 2 |
| Retrospective Cohort Study SEER-Medicare Population | Celgene Corporation | $578.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 62 | 192 | $47,407 | $10,768 |
Total Patients
62
Total Services
192
Medicare Billing
$10,768
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 130 | $36,068 | $8,218 | 22.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 23 | 62 | $11,339 | $2,550 | 22.5% |
About Dr. Christopher Cogle, MD
Dr. Christopher Cogle, MD is a Medical Oncology healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447291455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Cogle, MD has received a total of $33,817 in payments from pharmaceutical and medical device companies, with $32.27 received in 2024. These payments were reported across 21 transactions from 3 companies. The most common payment nature is "" ($20,221).
As a Medicare-enrolled provider, Cogle has provided services to 62 Medicare beneficiaries, totaling 192 services with total Medicare billing of $10,768. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Gainesville, FL
- Active Since 06/09/2006
- Last Updated 03/24/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1447291455
Products in Payments
- CC-486 (Drug) $17,501
- Revlimid (Drug) $14,002
- Vidaza (Drug) $2,142
- Wegovy (Drug) $96.81
- TIBSOVO (Drug) $43.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Gainesville
Dr. George Kim, M.d, M.D
Medical Oncology — Payments: $1.0M
Medical Oncology $1.0M
Dr. John Wingard, Md, MD
Medical Oncology — Payments: $147,953
Medical Oncology $147,953
Dr. Coy Heldermon, Md, MD
Medical Oncology — Payments: $47,064
Medical Oncology $47,064
Andrew Johnson, M.d, M.D
Medical Oncology — Payments: $21,882
Medical Oncology $21,882
Richard Locicero, M.d, M.D
Medical Oncology — Payments: $12,834
Medical Oncology $12,834
Devi Sampat, Md, MD
Medical Oncology — Payments: $10,292
Medical Oncology $10,292